We are live on
!
Find out more
RCM
Revelation Capital Management Portfolio holdings
AUM
$67.4M
This Fund
S&P 500
This Quarter
Est. Return
-8.86%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
–
Cap. Flow
+$125M
Cap. Flow
% of AUM
120.58%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
+$67.4M |
| 2 |
ME
23andMe Holding Co
ME
|
+$43.1M |
| 3 |
Neuropace
NPCE
|
+$8.66M |
| 4 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$4.44M |
| 5 |
Natera
NTRA
|
+$822K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
RC
MA
S4W
SGOM
VIM
ILCM
FWA
EVC
Revelation Capital Management's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for Revelation Capital Management, which disclosed 6 positions worth $104M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Singular Genomics Systems, Inc. Common Stock: 173,998 shares worth $60.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Revelation Capital Management's largest Q4 2021 buy was Singular Genomics Systems, Inc. Common Stock: 173,998 shares worth $60.3M.
- Revelation Capital Management's ten largest holdings make up 100% of its $104M portfolio in Q4 2021.
- Revelation Capital Management disclosed 6 positions in Q4 2021, its first 13F filing on record.
Based on Revelation Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.